IL319227A - Psilocin crystalline forms - Google Patents
Psilocin crystalline formsInfo
- Publication number
- IL319227A IL319227A IL319227A IL31922725A IL319227A IL 319227 A IL319227 A IL 319227A IL 319227 A IL319227 A IL 319227A IL 31922725 A IL31922725 A IL 31922725A IL 319227 A IL319227 A IL 319227A
- Authority
- IL
- Israel
- Prior art keywords
- psilocin
- crystalline forms
- crystalline
- forms
- psilocin crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/124—Acids containing four carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263375305P | 2022-09-12 | 2022-09-12 | |
| PCT/IB2023/059011 WO2024057193A1 (en) | 2022-09-12 | 2023-09-12 | Psilocin crystalline forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319227A true IL319227A (en) | 2025-04-01 |
Family
ID=90274467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319227A IL319227A (en) | 2022-09-12 | 2023-09-12 | Psilocin crystalline forms |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4587426A1 (en) |
| JP (1) | JP2025530158A (en) |
| AU (1) | AU2023343417A1 (en) |
| CA (1) | CA3267523A1 (en) |
| IL (1) | IL319227A (en) |
| WO (1) | WO2024057193A1 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB912715A (en) * | 1958-02-21 | 1962-12-12 | Sandoz Ltd | 4-hydroxytryptamines |
| US20080293695A1 (en) * | 2007-05-22 | 2008-11-27 | David William Bristol | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance |
| AU2022218986A1 (en) * | 2021-02-10 | 2023-09-21 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| CN117177959A (en) * | 2021-03-18 | 2023-12-05 | 赛本爱尔兰有限公司 | Nudity analogs, salts, compositions, and methods of use |
| CA3219041A1 (en) * | 2021-05-24 | 2022-12-01 | Canna-Chemistries Llc | Crystalline salts of psilocin |
| EP4486448A1 (en) * | 2022-03-04 | 2025-01-08 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US11667607B1 (en) * | 2022-06-30 | 2023-06-06 | Zylorion Health Inc. | Crystalline forms of compositions comprising psilocin and psilocybin |
-
2023
- 2023-09-12 IL IL319227A patent/IL319227A/en unknown
- 2023-09-12 WO PCT/IB2023/059011 patent/WO2024057193A1/en not_active Ceased
- 2023-09-12 JP JP2025514085A patent/JP2025530158A/en active Pending
- 2023-09-12 AU AU2023343417A patent/AU2023343417A1/en active Pending
- 2023-09-12 EP EP23864880.2A patent/EP4587426A1/en active Pending
- 2023-09-12 CA CA3267523A patent/CA3267523A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4587426A1 (en) | 2025-07-23 |
| JP2025530158A (en) | 2025-09-11 |
| AU2023343417A1 (en) | 2025-03-13 |
| CA3267523A1 (en) | 2024-03-21 |
| WO2024057193A1 (en) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202102360D0 (en) | Crystalline compound | |
| GB202200735D0 (en) | Compounds | |
| IL323224A (en) | Crystalline form | |
| IL321171A (en) | 2-oxoquinazoline crystalline forms | |
| GB202208643D0 (en) | Compounds | |
| IL319227A (en) | Psilocin crystalline forms | |
| GB202300021D0 (en) | Compounds | |
| GB202214796D0 (en) | Compounds | |
| GB202208151D0 (en) | Compounds | |
| GB202201996D0 (en) | Compounds | |
| GB202217726D0 (en) | Crystalline compound | |
| IL314730A (en) | Crystalline (+)-tetrabenazine | |
| GB202218027D0 (en) | Psilocin prodrugs | |
| GB202210427D0 (en) | Psilocin prodrugs | |
| GB202008588D0 (en) | Crystalline forms | |
| GB202317989D0 (en) | Novel crystalline salt forms | |
| GB202308164D0 (en) | Compounds | |
| GB202302871D0 (en) | Compounds | |
| GB202302237D0 (en) | Tryptophan-based compounds | |
| GB202300995D0 (en) | Compounds | |
| GB202301012D0 (en) | Compounds | |
| GB202301000D0 (en) | Compounds | |
| GB202301008D0 (en) | Compounds | |
| GB202301024D0 (en) | Compounds | |
| GB202300922D0 (en) | Compounds |